Vascular occlusion from biostimulators: what is known

The collagen biostimulator has become a protagonist of HOF: it promises skin quality, firmness and support with a gradual effect. With its popularity, so has grown the question every professional must be able to answer: what happens if the product enters a vessel, or compresses one? The honest answer is that our knowledge is smaller than we would like, and that the absence of an "undo button" changes how we think about safety. This page brings together what the review literature and reports describe, without injection protocols or doses.

The overview of products is in biostimulators: overview and the general concept in vascular occlusion. For broader complications, see complications with biostimulators.

Why does the biostimulator change the conversation about occlusion?

Three reasons combine.

The material is particulate. Biostimulators use particles or microspheres suspended in a vehicle, such as calcium hydroxyapatite, poly-L-lactic acid and polycaprolactone. If particles reach the circulation, they can occlude smaller vessels, and particle size weighs in on the hypothesis of how distal the blockage can be.

There is no enzymatic reversal. For hyaluronic acid, hyaluronidase is the main tool. For biostimulators, there is no equivalent enzyme, which narrows the therapeutic options to supportive measures and medical management of ischemia.

The vehicle is usually diluted and the volume large. Many biostimulators are injected in larger volumes and in varied planes, and this can increase the extent of a possible blockage or compression.

None of this means the procedure is unsafe by definition. It means the margin for error is smaller and prevention carries almost all the weight.

What does the literature allow us to state?

Honesty matters here. The evidence on occlusion from biostimulators comes mainly from case reports and case series and from consensus recommendations. That allows us to say the event exists and that the presentations resemble those of hyaluronic acid, but it does not allow us to calculate a reliable frequency or to claim which management is superior. To understand the limits of this kind of information, read levels of evidence in HOF and evidence on biostimulators.

What signs usually appear?

The signs follow the mechanism of ischemia, regardless of the product.

There is one detail: the biostimulator is usually injected in deeper planes and over wide areas, so the manifestation may be less evident on the surface in the first hours. In that scenario, disproportionate pain carries extra weight.

What to do when occlusion is suspected

Since no enzyme reverses the material, management is supportive and depends on medical evaluation. At review level, the organized steps are usually:

1. Stop the injection and add no material.
2. Assess the area quickly: color, pain, capillary refill, extent, eye or neurological signs.
3. Call for medical support and the clinic protocol, with early referral when there are visual symptoms, an extensive area or worsening.
4. Measures described in protocols, such as stimulating local circulation and systemic medications, appear in guidelines with limited evidence, and prescribing is the physician's decision.
5. Record times, findings, serial photos, product, lot and actions.
6. Follow closely in the following days, with wound care when needed.
7. Report the event according to health legislation in Brazil. See adverse event reporting (Notivisa).

Which areas call for more caution?

Caution follows the vascularization and the proximity of noble structures. In general, consensus discussions point to greater concern in areas with large-caliber arteries or connections to the ocular circulation, including the glabellar area, the forehead, the temples, the nose and the periorbital area. The risk map is in vascular danger zones of the face.

For specific areas, see:

• Biostimulator in the temples, with attention to superficial and deep vessels.
• Biostimulator in the forehead.
• Biostimulator in the under-eye area.
• Biostimulator in the cheeks and in the chin.
• Hydroxyapatite in the jawline.

The decision to treat a higher-risk area with a non-reversible material requires specific training and a candid discussion with the patient about alternatives.

Comparing with hyaluronic acid

The comparison is not a safety ranking. Each product has its indication, and the choice starts from the clinical goal. The point is to remember that the absence of reversal calls for doubled planning.

Prevention at review level

• Training and experience with the product and with the anatomy of the area.
• Conservative volumes and stages, instead of large amounts in one session.
• Attention to the skin throughout the session, watching color and capillary refill.
• Appropriate choice of instrument and product, discussed in cannula or needle.
• Patient screening: history of surgeries, scars, vascular and autoimmune diseases. See autoimmune diseases and fillers.
• Detailed consent, mentioning occlusion, necrosis and the absence of enzymatic reversal. The consent template for biostimulators can be adapted: biostimulator informed consent form, with legal review and review against your professional council's rules.
• Trained team and a written protocol.

How to talk to the patient

In Harmy

Summary

Vascular occlusion from biostimulators is rare, poorly quantified and hard to reverse. What is known: the signs are those of ischemia in general, hyaluronidase does not solve it, management is supportive and early referral matters. What to do: invest in training, conservative planning, watching during injection, clear consent and a medical support network defined before the first case.